Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Aclaris Therapeutics stock
Learn how to easily invest in Aclaris Therapeutics stock.
Aclaris Therapeutics Inc is a biotechnology business based in the US. Aclaris Therapeutics shares (ACRS) are listed on the NASDAQ and all prices are listed in US Dollars. Aclaris Therapeutics employs 57 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Aclaris Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ACRS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Aclaris Therapeutics stock price (NASDAQ: ACRS)Use our graph to track the performance of ACRS stocks over time.
Aclaris Therapeutics shares at a glance
|Latest market close||$10.50|
|52-week range||$9.26 - $30.38|
|50-day moving average||$13.28|
|200-day moving average||$17.25|
|Wall St. target price||$34.80|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.55|
Buy Aclaris Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Aclaris Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Aclaris Therapeutics price performance over time
|1 week (2022-01-19)||3.55%|
|1 month (2021-12-22)||N/A|
|3 months (2021-10-22)||N/A|
|6 months (2021-07-26)||-30.56%|
|1 year (2021-01-26)||-39.93%|
|2 years (2020-01-24)||568.79%|
|3 years (2019-01-25)||56.72%|
|5 years (2017-01-26)||27.04|
Aclaris Therapeutics financials
|Revenue TTM||$6.8 million|
|Gross profit TTM||$-27,989,000|
|Return on assets TTM||-21.71%|
|Return on equity TTM||-63.46%|
|Market capitalisation||$596.4 million|
TTM: trailing 12 months
Aclaris Therapeutics share dividends
We're not expecting Aclaris Therapeutics to pay a dividend over the next 12 months.
Aclaris Therapeutics share price volatility
Over the last 12 months, Aclaris Therapeutics's shares have ranged in value from as little as $9.26 up to $30.375. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aclaris Therapeutics's is 0.4921. This would suggest that Aclaris Therapeutics's shares are less volatile than average (for this exchange).
Aclaris Therapeutics overview
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. .
Aclaris Therapeutics in the news
Netflix shares fall near pre-pandemic level as investors fear slowing subscriber growth, competition
Stocks making the biggest moves midday: Netflix, Kohl's, Wynn Resorts, General Motors and more
RBC upgrades Comcast to outperform on subscriber growth
Frequently asked questionsWhat percentage of Aclaris Therapeutics is owned by insiders or institutions?
Currently 4.138% of Aclaris Therapeutics shares are held by insiders and 93.612% by institutions. How many people work for Aclaris Therapeutics?
Latest data suggests 57 work at Aclaris Therapeutics. When does the fiscal year end for Aclaris Therapeutics?
Aclaris Therapeutics's fiscal year ends in December. Where is Aclaris Therapeutics based?
Aclaris Therapeutics's address is: 640 Lee Road, Wayne, PA, United States, 19087 What is Aclaris Therapeutics's ISIN number?
Aclaris Therapeutics's international securities identification number is: US00461U1051 What is Aclaris Therapeutics's CUSIP number?
Aclaris Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00461U105
More guides on Finder
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
Dogecoin jumps 10% on word you can use it to buy Tesla merch
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Ask an Expert